QuantLogix ← TECH scorecard
📅 TECH Earnings Preview
Bio-Techne Corp Common Stock
Next report (est.)
11/23/2026
Countdown
27 days
EPS growth YoY
+0.0%
Revenue growth YoY
+1.3%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
08/24/2026 ±0.4% +0.1% over-priced
05/06/2026 ±4.4% -16.4% under-priced
02/04/2026 ±4.1% +6.3% under-priced
11/05/2025 ±3.4% -1.9% over-priced
08/22/2025 ±2.1% +5.7% under-priced
05/08/2025 ±4.9% +2.1% over-priced
02/06/2025 ±4.5% -0.3% over-priced
11/05/2024 ±4.7% +2.3% over-priced
Across these reports, options implied an average ±3.5% move vs an actual average of 4.4% — the stock stayed inside the implied band 63% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q4 FY2026 — $321M $55M
Q3 FY2026 $0.32 $311M $51M
Q2 FY2026 $0.24 $296M $38M
Q1 FY2026 $0.24 $287M $38M
Analyst posture
Buy / Strong Buy
6
Hold
14
Sell
0
Downward revisions — 9 net (vs 10 prior)
Live 5-factor engine read: Buy · 71/100 Full scorecard →
Get alerted before every TECH report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on TECH before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Bio-Techne Corp Common Stock (TECH) reports in 27 days, with the next report estimated for 11/23/2026. Across the last 8 reports, options priced an average ±3.5% earnings move while the stock actually moved 4.4% on average — the market has been roughly fair on TECH's earnings risk. Fundamentals into the print: EPS up 0.0% year-over-year, revenue up 1.3%. QuantLogix's live 5-factor engine currently reads TECH as a buy at 71/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →